Brimonidine/timolol
From Infogalactic: the planetary knowledge core
| Combination of | |
|---|---|
| Brimonidine | α2 adrenergic agonist |
| Timolol | Beta blocker |
| Clinical data | |
| Trade names | Combigan |
| AHFS/Drugs.com | entry |
| Pregnancy category |
|
| Legal status |
|
| Routes of administration |
Eye drops |
| Identifiers | |
| ATC code | S01ED51 (WHO) |
| PubChem | CID: 11387895 |
Brimonidine/timolol (INNs, trade name Combigan) are combination eye drops indicated for the treatment of glaucoma. It is a combination of brimonidine (an α2 adrenergic agonist) and timolol (a β adrenergic blocker), in concentrations of 0.2% and 0.5% respectively. Both substances work by decreasing the synthesis of aqueous humor.
Combigan is marketed and sold by Allergan.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Drugs that are a combination of chemicals
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Ophthalmology drugs
- Combination drugs
- Pharmacology stubs
